CTMX

CytomX Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · cytomx.com

$4.18

Mkt Cap $711.6M

52w Low $0.84 45.3% of range 52w High $8.21

50d MA $4.74 200d MA $3.84

P/E (TTM) -27.9x

EV/EBITDA -31.8x

P/B 5.8x

Debt/Equity 0.0x

ROE -17.5%

P/FCF -7.8x

RSI (14) —

ATR (14) —

Beta 2.48

50d MA $4.74

200d MA $3.84

Avg Volume 6.9M

About

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 t…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-0.08	-0.22	-175.0%	6.75	+2.5%	-19.3%	-34.8%	-29.2%	-34.1%	-33.9%	—
Nov 6, 2025	AMC	-0.05	-0.09	-82.5%	4.19	-9.3%	-13.6%	+0.0%	-2.1%	+1.0%	-7.9%	—
Aug 7, 2025	AMC	-0.06	-0.00	+98.0%	2.10	-2.4%	+11.9%	+10.0%	-11.4%	-15.2%	-16.2%	—
May 12, 2025	AMC	0.12	0.27	+116.3%	2.13	+1.9%	+17.4%	+11.7%	-6.1%	-4.7%	+0.0%	—
Mar 6, 2025	AMC	-0.23	0.22	+195.7%	0.62	+15.0%	+7.7%	+8.5%	+0.5%	-3.0%	-4.3%	—
Nov 7, 2024	AMC	-0.17	0.07	+141.2%	1.00	+15.0%	+9.0%	+4.0%	+4.0%	+1.0%	+0.0%	—
Aug 8, 2024	AMC	-0.14	-0.08	+42.9%	1.18	+0.8%	+1.7%	+0.8%	-1.7%	-1.7%	+0.8%	—
May 8, 2024	AMC	-0.08	0.17	+312.5%	4.19	-35.1%	-51.3%	-52.7%	-54.9%	-53.7%	-53.2%	—
Mar 11, 2024	AMC	0.00	0.01	+133.8%	2.51	-19.5%	-14.3%	-16.3%	-17.9%	-17.5%	-19.5%	—
Nov 7, 2023	AMC	-0.19	0.04	+121.1%	1.28	+0.8%	-2.3%	-6.2%	-8.6%	-3.9%	+0.0%	—
Aug 8, 2023	AMC	-0.20	-0.02	+90.0%	1.69	+0.0%	-3.6%	+1.2%	-0.6%	-3.0%	-5.9%	—
May 9, 2023	AMC	-0.11	-0.05	+54.9%	1.72	+3.5%	+5.8%	+2.9%	+3.5%	+5.8%	+2.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 23	Piper Sandler	Maintains	Overweight → Overweight	—	$4.45	$4.48	+0.7%	+0.2%	-4.7%	-5.2%	-0.7%	+1.6%
Mar 19	Barclays	Maintains	Overweight → Overweight	—	$4.40	$4.51	+2.5%	+8.6%	+1.1%	+1.4%	-3.6%	-4.1%
Mar 18	Guggenheim	Maintains	Buy → Buy	—	$5.45	$5.27	-3.3%	-19.3%	-12.3%	-18.3%	-18.2%	-22.2%
Mar 18	Jefferies	Maintains	Buy → Buy	—	$5.45	$5.27	-3.3%	-19.3%	-12.3%	-18.3%	-18.2%	-22.2%
Mar 17	Wedbush	Maintains	Outperform → Outperform	—	$6.75	$6.92	+2.5%	-19.3%	-34.8%	-29.2%	-34.1%	-33.9%
Mar 16	JP Morgan	Upgrade	Neutral → Overweight	—	$4.68	$6.92	+47.9%	+44.2%	+16.5%	-6.0%	+2.1%	-4.9%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.68	$6.92	+47.9%	+44.2%	+16.5%	-6.0%	+2.1%	-4.9%
Mar 9	Guggenheim	Maintains	Buy → Buy	—	$4.68	$4.61	-1.5%	+7.5%	+4.3%	+4.3%	+4.1%	+0.0%
Feb 4	Barclays	Maintains	Overweight → Overweight	—	$6.07	$6.19	+2.0%	-6.6%	-13.7%	-6.6%	-6.1%	-8.9%
Feb 4	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.07	$6.19	+2.0%	-6.6%	-13.7%	-6.6%	-6.1%	-8.9%
Jan 20	Barclays	Maintains	Overweight → Overweight	—	$5.39	$5.46	+1.3%	-0.4%	-1.9%	+6.1%	+2.8%	-0.9%
Jan 20	Piper Sandler	Maintains	Overweight → Overweight	—	$5.39	$5.46	+1.3%	-0.4%	-1.9%	+6.1%	+2.8%	-0.9%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.19	$4.19	+0.0%	-2.1%	+1.0%	-7.9%	-7.4%	-15.3%
Oct 21	Barclays	Maintains	Overweight → Overweight	—	$3.74	$3.90	+4.3%	-3.2%	-9.4%	-11.8%	-12.8%	-10.2%
May 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.13	$2.14	+0.5%	-3.3%	-4.2%	+0.0%	+4.7%	+0.0%
May 15	Piper Sandler	Maintains	Overweight → Overweight	—	$2.38	$2.50	+5.0%	-16.0%	-14.7%	-10.5%	-13.4%	-14.3%
May 15	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$2.38	$2.50	+5.0%	-16.0%	-14.7%	-10.5%	-13.4%	-14.3%
Apr 14	Piper Sandler	Maintains	Overweight → Overweight	—	$0.53	$0.55	+3.3%	+13.8%	+18.6%	+18.3%	+23.2%	+40.8%
Mar 7	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$0.62	$0.71	+15.0%	+7.7%	+8.5%	+0.5%	-3.0%	-4.3%
Jan 7	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.14	$1.15	+0.9%	-10.5%	-13.8%	-22.8%	-22.2%	-26.2%
May 28	Piper Sandler	Upgrade	Neutral → Overweight	—	$1.75	$1.92	+9.7%	+2.3%	+0.0%	+0.0%	-2.9%	+0.0%
May 9	Wedbush	Upgrade	Neutral → Outperform	—	$4.19	$2.72	-35.1%	-51.3%	-52.7%	-54.9%	-53.7%	-53.2%
May 9	BMO Capital	Maintains	Market Perform → Market Perform	—	$4.19	$2.72	-35.1%	-51.3%	-52.7%	-54.9%	-53.7%	-53.2%
May 6	Jefferies	Upgrade	Hold → Buy	—	$4.43	$4.89	+10.4%	-1.4%	-8.1%	-5.4%	-54.0%	-55.3%
May 1	BMO Capital	Maintains	Market Perform → Market Perform	—	$1.63	$3.25	+99.4%	+214.7%	+176.1%	+171.8%	+168.1%	+149.7%
Apr 22	JP Morgan	Upgrade	Underweight → Neutral	—	$1.67	$1.76	+5.4%	+0.0%	+0.6%	-2.4%	-4.2%	-4.8%
Mar 12	BMO Capital	Maintains	Market Perform → Market Perform	—	$2.51	$2.02	-19.5%	-14.3%	-16.3%	-17.9%	-17.5%	-19.5%
Mar 12	Wedbush	Maintains	Neutral → Neutral	—	$2.51	$2.02	-19.5%	-14.3%	-16.3%	-17.9%	-17.5%	-19.5%
Nov 9	Wedbush	Maintains	Neutral → Neutral	—	$1.25	$1.25	+0.0%	-4.0%	-6.4%	-1.6%	+2.4%	+3.2%
Nov 8	Wedbush	Upgrade	Neutral → Outperform	—	$1.28	$1.29	+0.8%	-2.3%	-6.2%	-8.6%	-3.9%	+0.0%
Aug 9	BMO Capital	Maintains	Market Perform → Market Perform	—	$1.69	$1.69	+0.0%	-3.6%	+1.2%	-0.6%	-3.0%	-5.9%
Mar 28	Mizuho	Maintains	Neutral → Neutral	—	$1.79	$1.48	-17.3%	-15.1%	-14.2%	-17.3%	-15.6%	-14.0%
Jan 6	BMO Capital	Maintains	Market Perform → Market Perform	—	$1.79	$2.96	+65.4%	+40.8%	+60.9%	+55.3%	+53.1%	+52.5%
Nov 14	BMO Capital	Downgrade	Outperform → Market Perform	—	$1.29	$1.25	-3.1%	-1.6%	-7.8%	-6.2%	+24.0%	+34.9%
Nov 10	JP Morgan	Downgrade	Overweight → Underweight	—	$1.24	$1.19	-4.0%	+1.6%	+4.0%	+2.4%	-4.0%	-2.4%
Jul 11	Cowen & Co.	Downgrade	Outperform → Market Perform	—	$1.30	$1.28	-1.5%	-1.5%	-1.5%	+0.0%	+7.7%	+15.4%
Jul 11	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$1.30	$1.28	-1.5%	-1.5%	-1.5%	+0.0%	+7.7%	+15.4%
Jul 7	BMO Capital	Maintains	Outperform → Outperform	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	Jefferies	Downgrade	Buy → Hold	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	Barclays	Maintains	Overweight → Overweight	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	BTIG	Maintains	Buy → Buy	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	Mizuho	Downgrade	Buy → Neutral	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	Piper Sandler	Downgrade	Overweight → Neutral	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jul 7	Wedbush	Downgrade	Outperform → Neutral	—	$1.97	$1.41	-28.4%	-37.6%	-34.0%	-35.0%	-35.0%	-34.0%
Jun 24	BMO Capital	Maintains	Outperform → Outperform	—	$1.87	$1.95	+4.3%	+1.6%	+3.7%	-0.5%	+0.0%	-2.1%
Mar 2	JP Morgan	Maintains	Overweight → Overweight	—	$3.54	$3.89	+9.9%	+14.1%	+7.9%	+4.8%	+6.2%	+7.6%
Jan 18	Barclays	Upgrade	Underweight → Overweight	—	$3.95	$4.18	+5.8%	-3.0%	+3.3%	+5.3%	+8.6%	+11.1%
Dec 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.87	$3.81	-1.6%	+4.7%	+9.0%	+9.3%	+12.1%	+15.5%
Nov 15	BTIG	Maintains	Buy → Buy	—	$7.02	$7.16	+2.0%	+3.4%	+5.3%	+5.0%	+2.8%	+4.6%
May 28	Barclays	Downgrade	Equal Weight → Underweight	—	$8.19	$7.69	-6.1%	-12.6%	-16.3%	-17.9%	-17.0%	-17.3%

Recent Filings

8-K

Unknown — 8-K Filing

Cortimelix raised capital through an offering to fund Varseta-M development and operations, diluting existing shareholders but providing runway for clinical progress and investor returns.

Mar 19

8-K

Unknown — 8-K Filing

CytomX announced a corporate action on March 16, 2026, but the incomplete filing lacks material details, making it impossible to assess impact on the stock until full disclosure is available.

Mar 16

Data updated apr 25, 2026 3:43am · Source: massive.com